Gene therapy, A targeted treatment for diabetic nephropathy

Current Medicinal Chemistry

Volumn 20, Issue 30, 2013, Pages 3774-3784

  Lin, X ^a,b,c,d   Tao, L ^d   Tang, D ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Diabetes; Diabetic nephropathy; Gene therapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANTISENSE OLIGODEOXYNUCLEOTIDE; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; FRESOLIMUMAB; NEPHRIN; OSTEOGENIC PROTEIN 1; PROTEIN KINASE C ALPHA; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; DIABETIC NEPHROPATHY; DIALYSIS; DOWN REGULATION; ENZYME ACTIVITY; GENE THERAPY; GLOMERULAR FILTRATION BARRIER; GLOMERULUS; GLOMERULUS FILTRATION; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; NONHUMAN; PODOCYTE; PROTEINURIA; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GENE TARGETING; GENETIC THERAPY; HUMANS;

EID: 84883380170     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990183     Document Type: Article

References (109)

1. Stitt-Cavanagh, E.; MacLeod, L.; Kennedy, C. The podocyte in diabetic kidney disease. ScientificWorldJournal, 2009, 9, 1127-1139.
2. Balakumar, P.; Arora, M.K.; Reddy, J.; Anand-Srivastava, M,B. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism. J. Cardiovasc. Pharmacol., 2009, 54, 129-138.
3. Leiter, L.A. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res. Clin. Pract., 2005, 68 Suppl 2, S3-S14.
4. Danesh, F.R.; Sadeghi, M.M.; Amro, N.; Philips, C.; Zeng, L.; Lin, S.; Sahai, A.; Kanwar, Y.S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci. U S A., 2002, 99, 8301-8305.
5. Forbes, J.M.; Thallas, V.; Thomas, M.C.; Founds, H.W.; Burns, W.C.; Jerums, G.; Cooper, M.E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J., 2003, 17, 1762-1764.
6. Lewis, E.J.; Lewis, J.B. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin. Exp. Nephrol., 2003, 7, 1-8.
7. Remuzzi, G.; Ruggenenti, P.; Perna, A.; Dimitrov, B.D.; de Zeeuw, D.; Hille, D.A.; Shahinfar, S.; Carides, G.W.; Brenner, B.M. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol., 2004, 15, 3117-3125.
8. Ruggenenti, P.; Fassi, A.; Ilieva, A.P.; Bruno, S.; Iliev, I.P.; Brusegan, V.; Rubis, N,.; Gherardi, G.; Arnoldi, F.; Ganeva, M.; Ene-Iordache, B.; Gaspari, F.; Perna, A.; Bossi, A.; Trevisan, R.; Dodesini, A.R.; Remuzzi, G. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2004, 351, 1941-1951.
9. Parving, H.H.; Mauer, M.; Ritz, E. Diabetic nephropathy. In: The Kidney, 7th Ed., edited by Brenner BM, Philadelphia WB Saunders, p1777-1818, 2004.
10. Alsaad, K.O.; Herzenberg, A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J. Clin. Pathol., 2007, 60, 18-26.
11. Quaggin, S.E.; Coffman, T.M. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? J. Am. Soc. Nephrol., 2008, 18, 364-366.
12. Jefferson, J.A.; Shankland, S.J.; Pichler, R.H. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int., 2008, 74, 22-36.
13. Remuzzi, G.; Benigni, A.; Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest., 2006, 116, 288-296.
14. Haraldsson, B.; Nyström, J.; Deen, W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev., 2008, 88, 451-487.
15. Schlondorff, D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J., 1987, 1, 272-281.
16. Cove-Smith, A.; Hendry, B.M. The regulation of mesangial cell proliferation. Nephron. Exp. Nephrol., 2008, 108, e74-e79.
17. Brosius, F.C. 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord., 2008, 9, 245-254.
18. Wiggins, R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int., 2007, 71, 1205-1214.
19. Reiser, J.; Gupta, V.; Kistler, A.D. Toward the development of podocyte-specific drugs. Kidney Int., 2010, 77, 662-668.
20. Bohle, A.; Wehrmann, M.; Bogenschütz, O.; Batz, C.; Müller, C.A.; Müller, G.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol. Res. Pract., 1991, 187, 251-259.
21. Meyer, T.W.; Bennett, P.H.; Nelson, R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia, 1999, 42, 1341-1344.
22. White, K.E.; Bilous, R.W.; Marshall, S.M.; El Nahas, M.; Remuzzi, G.; Piras, G.; De Cosmo, S.; Viberti, G. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes, 2002, 51, 3083-3089.
23. Pagtalunan, M.E.; Miller, P.L.; Jumping-Eagle, S.; Nelson, R.G.; Myers, B.D.; Rennke, H.G.; Coplon, N.S.; Sun, L.; Meyer, T.W. Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest., 1997, 99, 342-348.
24. Reeves, W.B.; Andreoli, T.E. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc. Natl. Acad. Sci. U S A., 2000, 97, 7667-7669.
25. Tesch, G.H.; Nikolic-Paterson, D.J. Recent insights into experimental mouse models of diabetic nephropathy. Nephron. Exp. Nephrol., 2006, 104, e57-e62.
26. Daneshgari, F.; Leiter, E.H.; Liu, G.; Reeder, J. Animal models of diabetic uropathy. J. Urol., 2009, 182, S8-S13.
27. Sharma, K.; McCue, P.; Dunn, S.R. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Renal. Physiol., 2003, 284, F1138-F1144.
28. Allen, T.J.; Cooper, M.E.; Lan, H.Y. Use of genetic mouse models in the study of diabetic nephropathy. Curr. Atheroscler. Rep., 2004, 6, 197-202.
29. Tesch, G.H.; Lim, A.K. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2011, 300, F301-F310.
30. McGowan, T.A.; Zhu, Y.; Sharma, K. Transforming growth factorbeta: a clinical target for the treatment of diabetic nephropathy. Curr. Diab. Rep., 2004, 4, 447-454.
31. Ziyadeh, F.N. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J. Am. Soc. Nephrol., 2004, 15 Suppl 1, S55-S57.
32. Nakamura, T.; Fukui, M.; Ebihara, I.; Osada, S.; Nagaoka, I.; Tomino, Y.; Koide, H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes, 1993, 42, 450-456.
33. Park, I.S.; Kiyomoto, H.; Abboud, S.L.; Abboud, H.E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes, 1999, 46, 473-480.
34. Border, W.A.; Noble, N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int., 1998, 54, 1390-1391.
35. Hills, C.E.; Squires, P.E. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev., 2011, 22, 131-139.
36. Ziyadeh, F.N.; Hoffman, B.B.; Han, D.C.; Iglesias-De La Cruz, M.C.; Hong, S.W.; Isono, M.; Chen, S.; McGowan, T.A.; Sharma, K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U S A., 2000, 97, 8015-8020.
37. Sharma, K.; Jin, Y.; Guo, J.; Ziyadeh, F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes, 1996, 45, 522-530.
38. Hill, C.; Flyvbjerg, A.; Rasch, R.; Bak, M.; Logan, A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J. Endocrinol., 2001, 170, 647-651.
39. Benigni, A.; Zoja, C.; Campana, M.; Corna, D.; Sangalli, F.; Rottoli, D.; Gagliardini, E.; Conti, S.; Ledbetter, S.; Remuzzi, G. Beneficial effect of TGF-beta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron. Exp. Nephrol., 2006, 104, e158-e168.
40. Trachtman, H.; Fervenza, F.C.; Gipson, D.S.; Heering, P.; Jayne, D.R.; Peters, H.; Rota, S.; Remuzzi, G.; Rump, L.C.; Sellin, L.K.; Heaton, J.P.; Streisand, J.B.; Hard, M.L.; Ledbetter, S.R.; Vincenti, F. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int., 2011, 79, 1236-1243.
41. Bagchus, W.M.; Hoedemaeker, P.J.; Rozing, J.; Bakker, W.W. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest., 1986, 55, 680-687.
42. Border, W.A.; Okuda, S.; Languino, L.R.; Sporn, M.B.; Ruoslahti, E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature, 1990, 346, 371-374.
43. Okuda, S.; Languino, L.R.; Ruoslahti, E.; Border, W.A. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J. Clin. Invest., 1990, 86, 453-462.
44. Yamamoto, T.; Noble, N.A.; Miller, D.E.; Border, W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int., 1994, 45, 916-927.
45. Akagi, Y.; Isaka, Y.; Arai, M.; Kaneko, T.; Takenaka, M.; Moriyama, T.; Kaneda, Y.; Ando, A.; Orita, Y.; Kamada, T.; Ueda, N.; Imai, E. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int., 1996, 50, 148-155.
46. Jeong, H.S.; Park, K.K.; Park, K.K.; Kim, S.P.; Choi, I.J.; Lee, I.K.; Kim, H.C. Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney. J. Korean Med. Sci., 2004, 19, 374-383.
47. Kushibiki, T.; Nagata-Nakajima, N.; Sugai, M.; Shimizu, A.; Tabata, Y. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J. Control Release., 2005, 105, 318-331.
48. Kim, H.W.; Kim, B.C.; Song, C.Y.; Kim, J.H.; Hong, H.K.; Lee, H.S. Heterozygous mice for TGF-betaIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int., 2004, 66, 1859-1865.
49. Kondo, T.; Takemura, G.; Kosai, K.; Ohno, T.; Takahashi, T.; Esaki, M.; Goto, K.; Maruyama, R.; Murata, I.; Minatoguchi, S.; Fujiwara, T.; Fujiwara, H. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice. Clin. Exp. Pharmacol. Physiol., 2008, 35, 1288-1293.
50. López-Casillas, F.; Wrana, J.L.; Massagué, J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell, 1993, 73, 1435-1444.
51. Velasco-Loyden, G.; Arribas, J.; López-Casillas, F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J. Biol. Chem., 2004, 279, 7721-7733.
52. Vilchis-Landeros, M.M.; Montiel, J.L.; Mendoza, V.; Mendoza- Hernández, G.; López-Casillas, F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J., 2001, 355(Pt 1), 215-222.
53. Juárez, P.; Vilchis-Landeros, M.M.; Ponce-Coria, J.; Mendoza, V, Hernández-Pando R, Bobadilla NA, López-Casillas F. Soluble betaglycan reduces renal damage progression in db/db mice. Am. J. Physiol. Renal. Physiol., 2007, 292, F321-F329.
54. Mizuno, S.; Matsumoto, K.; Nakamura, T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int., 2001, 59, 1304-1314.
55. Yang, J.; Dai, C.; Liu, Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther., 2001, 8, 1470-1479.
56. Yoo, T.H.; Li, J.J.; Kim, J.J.; Jung, D.S.; Kwak, S.J.; Ryu, D.R.; Choi, H.Y.; Kim, J.S.; Kim, H.J.; Han, S.H.; Lee, J.E.; Han, D.S.; Kang. S.W. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int., 2007, 71, 1019-1027.
57. Ka, S.M.; Yeh, Y.C.; Huang, X.R.; Chao, T.K.; Hung, Y.J.; Yu, C.P.; Lin, T.J.; Wu, C.C.; Lan, H.Y.; Chen, A. Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia, 2012, 55, 509-519.
58. Diez-Sampedro, A.; Lenz, O.; Fornoni, A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am. J. Kidney Dis., 2011, 58, 637-646.
59. Thomas, M.C. Pathogenesis and progression of proteinuria. Contrib. Nephrol., 2011, 170, 48-56.
60. Susztak, K.; Raff, A.C.; Schiffer, M.; Böttinger, E.P. Glucoseinduced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 2006, 55, 225-233.
61. Kwoh, C.; Shannon, M.B.; Miner, J.H.; Shaw, A. Pathogenesis of nonimmune glomerulopathies. Annu. Rev. Pathol., 2006, 1, 349-374.
62. Wolf, G.; Chen, S.; Ziyadeh, F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes, 2005, 54, 1626-1634.
63. Flyvbjerg, A.; Dagnaes-Hansen, F.; De Vriese, A.S.; Schrijvers, B.F.; Tilton, R.G.; Rasch, R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes, 2002, 51, 3090-3094.
64. Mathieson, P.M. The podocyte as a target for therapies - new and old. Nat. Rev. Nephrol., 2011, 8, 53-56.
65. Sakoda, M.; Itoh, H.; Ichihara, A. Podocytes as a target of prorenin in diabetes. Curr. Diabetes Rev., 2011, 7, 17-21.
66. Reddy, G.R.; Kotlyarevska, K.; Ransom, R.F.; Menon, .RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr. Opin. Nephrol. Hypertens., 2008, 17, 32-36.
67. Zenker, M.; Machuca, E.; Antignac, C. Genetics of nephritic syndrome: new insights into molecules acting at the glomerular filtration barrier. J. Mol. Med., 2009, 87, 849-857.
68. Welsh, G.I.; Saleem, M.A. Nephrin-signature molecule of the glomerular podocyte? Pathol., 2010, 220, 328-337.
69. Kim, J.J.; Li, J.J.; Jung, D.S.; Kwak, S.J.; Ryu, D.R.; Yoo, T.H.; Han, S.H.; Choi, H.Y.; Kim, H.J.; Han, D.S.; Kang, S.W. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J. Am. Soc. Nephrol., 2007, 18, 2303-2310.
70. Koop, K.; Eikmans, M.; Baelde, H.J.; Kawachi, H.; De Heer, E.; Paul, L.C.; Bruijn, J.A. Expression of podocyte-associated molecules in acquired human kidney diseases. J. Am. Soc. Nephrol., 2003, 14, 2063-2071.
71. Doublier, S.; Salvidio, G.; Lupia, E.; Ruotsalainen, V.; Verzola, D.; Deferrari, G.; Camussi, G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes, 2003, 52, 1023-1030.
72. Tossidou, I.; Teng, B.; Menne, J.; Shushakova, N.; Park, J.K.; Becker, J.U.; Modde, F.; Leitges, M.; Haller, H.; Schiffer, M. Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis. PLoS One, 2010, 5: e10185.
73. Quack, I.; Woznowski, M.; Potthoff, S.A.; Palmer, R.; Königshausen, E.; Sivritas, S.; Schiffer, M.; Stegbauer, J.; Vonend. O.; Rump, L.C.; Sellin, L. PKC alpha mediates beta-arrestin2-dependent nephrin endocytosis in hyperglycemia. J. Biol. Chem., 2011, 286, 12959-12970.
74. Menne, J.; Meier, M.; Park, J.K.; Boehne, M.; Kirsch, T.; Lindschau, C.; Ociepka, R.; Leitges, M.; Rinta-Valkama, J.; Holthofer, H.; Haller, H. Nephrin loss in experimental diabetic nephropathy is preventedby deletion of protein kinase C alpha signaling in-vivo. Kidney Int., 2006, 70, 1456-1462.
75. Steffes, M.W.; Schmidt, D.; McCrery, R.; Basgen, J.M. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int., 2001, 59, 2104-2113.
76. Chuang, P.Y.; Yu, Q.; Fang, W.; Uribarri, J.; He, J.C. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int., 2007, 72, 965-976.
77. Niranjan, T.; Bielesz, B.; Gruenwald, A.; Ponda, M.P.; Kopp, J.B.; Thomas, D.B.; Susztak, K. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med., 2008, 14, 290-298.
78. Wendt, T.M.; Tanji, N.; Guo, J.; Kislinger, T.R.; Qu, W.; Lu, Y.; Bucciarelli, LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth, P.P.; Stern, D.M.; D'Agati, V.D.; Schmidt, A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol., 2003, 162, 1123-1137.
79. Myint, K.M.; Yamamoto, Y.; Doi, T.; Kato, I.; Harashima, A.; Yonekur,a H.; Watanabe, T.; Shinohara, H.; Takeuchi, M.; Tsuneyama, K.; Hashimoto, N.; Asano, M.; Takasawa, S.; Okamoto, H.; Yamamoto, H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes, 2006, 55, 2510-2522.
80. De Petris, L.; Hruska, K.A.; Chiechio, S.; Liapis, H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol. Dial. Transplant., 2007, 22, 3442-3450.
81. Mitu, G.M.; Wang, S.; Hirschberg, R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am. J. Physiol. Renal. Physiol., 2007, 293, F1641-F1648.
82. Wang, S.; Chen, Q.; Simon, T.C.; Strebeck, F.; Chaudhary, L.; Morrissey, J.; Liapis, H.; Klahr, S.; Hruska, K.A. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int., 2003, 63, 2037-2049.
83. Wang, S.; de Caestecker, M.; Kopp, J.; Mitu, G.; Lapage, J.; Hirschberg, R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol., 2006, 17, 2504-2512.
84. Ito, Y.; Aten, J.; Bende, R.J.; Oemar, B.S.; Rabelink, T.J.; Weening, J.J.; Goldschmeding, R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int., 1998, 53, 853-861.
85. Riser, B.L.; Denichilo, M.; Cortes, P.; Baker, C.; Grondin, J.M.; Yee, J.; Narins, R.G. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol., 2000, 11, 25-38.
86. Nguyen, T.Q.; Tarnow, L.; Andersen, S.; Hovind, P.; Parving. H.H.; Goldschmeding, R.; van Nieuwenhoven, F.A. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2006, 29, 83-86.
87. Nguyen, T.Q.; Tarnow, L.; Jorsal, A.; Oliver, N.; Roestenberg, P.; Ito, Y.; Parving, H.H.; Rossing, P.; van Nieuwenhoven, F.A.; Goldschmeding, R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care, 2008, 31, 1177-1182.
88. Nguyen, T.Q.; Roestenberg, P.; van Nieuwenhoven, F.A.; Bovenschen, N.; Li, Z.; Xu, L.; Oliver, N.; Aten, J.; Joles, J.A.; Vial, C.; Brandan, E.; Lyons, K.M.; Goldschmeding, R. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol., 2008, 19, 2098-2107.
89. Guha, M.; Xu, Z.G.; Tung, D.; Lanting, L.; Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J., 2007, 21, 3355-3368.
90. Durvasula, R.V.; Shankland, S.J. Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal. Physiol., 2008, 294, F830-F839.
91. Pavenstädt, H.; Kriz, W.; Kretzler, M. Cell biology of the glomerular podocyte. Physiol. Rev., 2003, 83, 253-307.
92. Ding, G.; Reddy, K.; Kapasi, A.A.; Franki, N.; Gibbons, N.; Kasinath, B.S.; Singhal, P.C. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am. J. Physiol. Renal. Physiol., 2002, 283, F173-F180.
93. Hoffmann, S.; Podlich, D.; Hähnel, B.; Kriz, W.; Gretz, N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol., 2004, 15, 1475-1487.
94. Mifsud, S.A.; Allen, T.J.; Bertram, J.F.; Hulthen, U.L.; Kelly, D.J.; Cooper, M.E.; Wilkinson-Berka, J.L.; Gilbert, R.E. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia, 2001, 44, 878-882.
95. Kelly, D.J.; Aaltonen, P.; Cox, A.J.; Rumble, J.R.; Langham, R.; Panagiotopoulos, S.; Jerums, G.; Holthöfer, H.; Gilbert, R.E. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol. Dial. Transplant., 2002, 17, 1327-1332.
96. Batlle, D.; Wysocki, J.; Soler, M.J.; Ranganath, K. Angiotensinconverting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int., 2012, 81, 520-528.
97. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R.E.; Acton, S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res., 2000, 87, E1-E9.
98. Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turne, A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275, 33238-33243.
99. Oudit, G.Y.; Liu, G.C.; Zhong, J.; Basu, R.; Chow, F.L.; Zhou, J.; Loibner, H.; Janzek, E.; Schuster, M.; Penninger, J.M.; Herzenberg, A.M.; Kassiri, Z.; Scholey, J.W. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes, 2010, 59, 529-538.
100. Liu, C.X.; Hu, Q.; Wang, Y.; Zhang, W.; Ma, Z.Y.; Feng, J.B.; Wang, R.; Wang, X.P.; Dong, B.; Gao, F.; Zhang, M.X.; Zhang, Y. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol. Med., 2011, 17, 59-69.
101. Oudit, G.Y.; Herzenberg, A.M.; Kassiri, Z.; Wong, D.; Reich, H.; Khokha, R.; Crackower, M.A.; Backx, P.H.; Penninger, J,M,; Scholey, J.W. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol., 2006, 168, 1808-1820.
102. Wong, D.W.; Oudit, G.Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q.C.; Backx, P.H.; Penninger, J.M.; Herzenberg, A.M.; Scholey, J.W. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol., 2007, 171, 438-451.
103. Ye, M.; Wysocki, J.; William, J.; Soler, M.J.; Cokic, I.; Batlle, D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol., 2006, 17, 3067-3075.
104. Nadarajah, R.; Milagres, R.; Dilauro, M.; Gutsol, A.; Xiao, F.; Zimpelmann, J.; Kennedy, C.; Wysocki, J.; Batlle, D.; Burns, K.D. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int., 2012, 82, 292-303.
105. Harris, R.C. Podocyte ACE2 protects against diabetic nephropathy. Kidney Int., 2012, 82, 255-256.
106. Reich, H.N.; Oudit, G.Y.; Penninger, J.M.; Scholey, J.W.; Herzenberg, A.M. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int., 2008, 74, 1610-1616.
107. Eyre, J.; Ioannou, K.; Grubb, B.D.; Saleem, M.A.; Mathieson, P.W.; Brunskill, N.J.; Christensen, E.I.; Topham, P.S. Statinsensitive endocytosis of albumin by glomerular podocytes. Am. J. Physiol. Renal Physiol., 2007, 292, F674-F681.
108. Akilesh, S.; Huber, T.B.; Wu, H.; Wang, G.; Hartleben, B.; Kopp, J.B.; Miner, J.H.; Roopenian, D.C.; Unanue, E.R.; Shaw, A.S. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl. Acad. Sci. U S A., 2008, 105, 967-972.
109. Hauser, P.V.; Pippin, J.W.; Kaiser, C.; Krofft, R.D.; Brinkkoetter, P.T.; Hudkins, K.L.; Kerjaschki, D.; Reiser, J.; Alpers, C.E.; Shankland, S.J. Novel siRNA delivery system to target podocytes in vivo. PLoS One, 2010, 5, e9463.